Studies on the antiparkinsonism efficacy of lergotrile.
The antiparkinsonian activity of lergotrile mesylate, a presumed dopaminergic receptor stimulating agent, was investigating in monkeys with surgically induced tremor and in parkinsonian patients. The administration of lergotrile resulted in a dose-dependent reduction in the intensity of tremor in the monkeys. In 13 patients with Parkinson's disease treated with lergotrile (up to 12 mg a day), overall improvement was observed in five. Tremor was the main clinical feature to benefit, and the improvement reached statistical significance. In a subgroup of four patients treated with a higher dose of lergotrile (up to 20 mg a day), further improvement in rigidity and bradykinesia was noted, but again, only improvement in tremor was statistically significant. Adverse effects included orthostatic hypotension, behavioral alterations, and nausea and vomiting. These were severe enough to result in drug withdrawal in three patients.
D000097:Acetonitriles / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D000368:Aged; D000818:Animals; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D004873:Ergolines / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D005684:Gait / Q000187:drug effects; D000882:Haplorhini; D006801:Humans; D008297:Male; D008698:Mesylates / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D008875:Middle Aged; D009127:Muscle Rigidity / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy*; D011388:Prolactin / Q000378:metabolism*; D011955:Receptors, Drug; D014202:Tremor / Q000188:drug therapy
D000097:Acetonitriles; D004873:Ergolines; D008698:Mesylates; D011955:Receptors, Drug; D011388:Prolactin; D004298:Dopamine